SofWave Medical Ltd (SOFWF) Fair Value & Analysis
Healthcare · US · Market cap $581M
SofWave Medical Ltd
SOFWF · US
Fair value as of: Jul 19, 2026
From 24 valuation models · updated 22 days ago
Share price −20.0% over the past month.
A strong business, but screening 74% overvalued on our models.
What matters now
- A high-quality business (quality 81/100), yet the market already pays well above fair value. Quality at a full price, with little margin of safety.
- The price sits above even our optimistic bull case ($3.78). The favourable scenario is already priced in.
Price vs Fair Value (5 months)
White line = price, green steps = our fair value per fiscal year. As of Jul 19, 2026.
How to read this chart
5‑month range $10.90 – $16.25 · fair‑value band $2.27 – $3.78 · the $11.47 price screens above the $3.02 fair value. As of Jul 19, 2026.
Analysis
SofWave Medical Ltd (SOFWF) currently trades at $11.47, while our model-based Fair Value estimate is $3.02, implying the stock looks roughly 73.7% overvalued today. The Quality Score stands at 81/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, SofWave Medical Ltd generated revenue of $95.4M at a net margin of 8.2%. Revenue grew 46.4% year over year. It earns a return on equity of 26.5%. The stock trades on a trailing P/E of 80.0. Fundamentals as of Jul 19, 2026
Our scenario range runs from $2.27 (bear case) to $3.78 (bull case); at $11.47, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 29% below its 52-week high and 5% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -74%, SOFWF screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models ($7.07) versus Asset-Based ($0.6000). Highest evidence: Growth DCF (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 19, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 80 · Market factors (momentum, volatility) 35
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally.
Full company description
SofWave Medical Ltd. engages in the development, production, marketing, and distribution of non-invasive medical technology for skin firming and rejuvenation, tissue renewal, treatment of muscle, aging, and other physiological change in Israel, the United States, Europe, Southeast Asia, the Middle East, and internationally. The company offers an ultrasound technology that induces coagulation and subsequent revitalization for regenerated skin under the SUPERB brand; and non-invasive muscle toning technology under the Pure Impact VIP brand. It serves plastic surgeons, dermatologists, and other physicians who perform aesthetic treatments on patients. It also provides technical and clinical product support services. The company was incorporated in 2015 and is based in Yokneam Illit, Israel.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
SofWave Medical Ltd reported revenue of $87.6M in FY2025 versus $35.6M in FY2022, a compound +35.0%/yr. Reported net income was $5.5M in FY2025.
SOFWF screens 74% overvalued. Compare with Abbott Laboratories, →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 19, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare SofWave Medical Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SofWave Medical Ltd (SOFWF) overvalued or undervalued?
What is the fair value of SOFWF?
What is the quality score of SOFWF?
What is the revenue of SofWave Medical Ltd (SOFWF)?
What is the net profit margin of SOFWF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SofWave Medical Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.